Drug
Bleomycin
CI-DRUG-00000668Explore in graph →CHEMBL6067492 Approved
Regulatory
Approvals (6)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as BLEOMYCIN FOR INJECTION (DIN 02265982) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 20, 2009 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as BLEOMYCIN FOR INJECTION USP (DIN 02131692) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 12, 1998 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as BLENOXANE PWS 15UNIT (DIN 00258482) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Oct 19, 2011 |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated yesterdaySource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 20 | 10 | 54 | 122 | 6 | CA, US | Mar 12, 1998 | 1989-04 |
| Hodgkin Lymphoma | Phase3 | Phase 3 | 7 | 2 | 11 | 24 | 0 | — | — | Jan 25, 1994 |
| Malignant Ovarian Neoplasm | Phase3 | Phase 3 | 3 | 3 | 5 | 7 | 0 | — | — | 1989-04 |
| Malignant Testicular Neoplasm | Phase3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (125)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006916 | Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme | terminated | Phase 2 | 19 | Radiation Therapy Oncology GroupNETWORK | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04139070 | Electrochemotherapy for Non-curable Gastric Cancer | unknown | Phase 1 |